跳至主要内容
临床试验/NCT03565302
NCT03565302Unknown不适用

Gender-specific Role of the beta2-adrenergic Stimulation With Short- or Long-acting Selective Agonist in Relation to Muscle Remodelling, Function, Performance, and Anti-doping

Morten Hostrup, PhD1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2018年6月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
72
试验地点
1
主要终点
Proteome enrichment

研究概览

简要总结

The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy men and women, aged 18-45 years
  • VO2max >55 ml/kg/min for men and >50 ml/kg/min for women (± biologic and techinical variation of 5.6% (Katch et al. 1982)
  • Body Mass Index (BMI) < 26

排除标准

  • Chronic user of beta2-agonist or allergy towards study drugs
  • Serious adverse side effects of the used study drug
  • Chronic disease that by the project physician would affect any of the outcomes of the study
  • Chronic use of prescription medication (other than contraceptives for women)
  • Pregnancy

研究组 & 干预措施

Short acting beta2-agonist

Experimental

Subjects are treated with short-acting beta2-agonist terbutaline

干预措施: Terbutaline (Drug)

Control

Placebo Comparator

Subjects receive placebo treatment

干预措施: Placebo (Other)

Long acting beta2-agonist

Experimental

Subjects are treated with long-acting beta2-agonist formoterol

干预措施: Formoterol (Drug)

结局指标

主要结局

Proteome enrichment

时间窗: Baseline and 6 weeks

Change in enrichment (measured in muscle biopsies and assessed using GO annotations)

次要结局

  • Body composition(Baseline, 2 weeks, 4 weeks and 6 weeks)
  • Maximal oxygen consumption (VO2max)(Baseline, 2 weeks, 4 weeks and 6 weeks)

研究者

发起方
Morten Hostrup, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Morten Hostrup, PhD

Associate Professor

University of Copenhagen

研究点 (1)

Loading locations...

相似试验

Beta2-adrenergic Agonism and Muscle Remodelling | 临床试验